309 related articles for article (PubMed ID: 17912529)
1. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.
Knowles MA
World J Urol; 2007 Dec; 25(6):581-93. PubMed ID: 17912529
[TBL] [Abstract][Full Text] [Related]
2. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
[TBL] [Abstract][Full Text] [Related]
3. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
Iyer G; Milowsky MI
Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
[TBL] [Abstract][Full Text] [Related]
5. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.
Ahmad F; Mahal V; Verma G; Bhatia S; Das BR
Cancer Rep (Hoboken); 2018 Oct; 1(3):e1130. PubMed ID: 32721083
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS; Kim K; Kwon GY; Lee SJ; Park SH
BMC Urol; 2018 Jul; 18(1):68. PubMed ID: 30064409
[TBL] [Abstract][Full Text] [Related]
7. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.
Tomlinson DC; Baldo O; Harnden P; Knowles MA
J Pathol; 2007 Sep; 213(1):91-8. PubMed ID: 17668422
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer.
Pandith AA; Shah ZA; Siddiqi MA
Urol Oncol; 2013 May; 31(4):398-406. PubMed ID: 20822928
[TBL] [Abstract][Full Text] [Related]
9. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
Bodoor K; Ghabkari A; Jaradat Z; Alkhateeb A; Jaradat S; Al-Ghazo MA; Matalka I; Musleh H; Haddad Y
Cancer Epidemiol; 2010 Dec; 34(6):724-32. PubMed ID: 20542753
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
[TBL] [Abstract][Full Text] [Related]
11. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and Prognostic Implications of FGFR3
Geelvink M; Babmorad A; Maurer A; Stöhr R; Grimm T; Bach C; Knuechel R; Rose M; Gaisa NT
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30154342
[TBL] [Abstract][Full Text] [Related]
13. The role of mutations and overexpression of the fibroblast growth factor receptor-3 in bladder cancer.
Wang QY; Zhao Y; Zhang R
Minerva Med; 2015 Dec; 106(6):333-7. PubMed ID: 26542242
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.
Al-Ahmadie HA; Iyer G; Janakiraman M; Lin O; Heguy A; Tickoo SK; Fine SW; Gopalan A; Chen YB; Balar A; Riches J; Bochner B; Dalbagni G; Bajorin DF; Reuter VE; Milowsky MI; Solit DB
J Pathol; 2011 Jun; 224(2):270-9. PubMed ID: 21547910
[TBL] [Abstract][Full Text] [Related]
15. FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.
Foth M; Ismail NFB; Kung JSC; Tomlinson D; Knowles MA; Eriksson P; Sjödahl G; Salmond JM; Sansom OJ; Iwata T
J Pathol; 2018 Nov; 246(3):331-343. PubMed ID: 30043421
[TBL] [Abstract][Full Text] [Related]
16. Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma.
Bakkar AA; Allory Y; Iwatsubo Y; de Medina SG; Maille P; Khreich N; Riou A; Leroy K; Vordos D; Abbou CC; Andujar P; Billebaud T; Chammings S; Conso F; De La Taille A; Fontaine E; Gattegno B; Ravery V; Sibony M; Radvanyi F; Chopin DK; Pairon JC
Mol Carcinog; 2010 Jan; 49(1):25-31. PubMed ID: 19722178
[TBL] [Abstract][Full Text] [Related]
17. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.
Kompier LC; van der Aa MN; Lurkin I; Vermeij M; Kirkels WJ; Bangma CH; van der Kwast TH; Zwarthoff EC
J Pathol; 2009 May; 218(1):104-12. PubMed ID: 19156776
[TBL] [Abstract][Full Text] [Related]
18. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.
Hodgson A; van Rhijn BWG; Kim SS; Ding C; Saleeb R; Vesprini D; Liu SK; Yousef GM; van der Kwast TH; Xu B; Downes MR
Pathol Res Pract; 2020 Nov; 216(11):153186. PubMed ID: 32861170
[TBL] [Abstract][Full Text] [Related]
19. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
[TBL] [Abstract][Full Text] [Related]
20. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.
Tomlinson DC; Hurst CD; Knowles MA
Oncogene; 2007 Aug; 26(40):5889-99. PubMed ID: 17384684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
